| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SIRPG |
| Uniprot No | Q9P1W8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-364aa |
| 氨基酸序列 | EEELQMIQPEKLLLVTVGKTATLHCTVTSLLPVGPVLWFRGVGPGRELIY NQKEGHFPRVTTVSDLTKRNNMDFSIRISSITPADVGTYYCVKFRKGSPE NVEFKSGPGTEMALGAKPSAPVVLGPAARTTPEHTVSFTCESHGFSPRDI TLKWFKNGNELSDFQTNVDPTGQSVAYSIRSTARVVLDPWDVRSQVICEV AHVTLQGDPLRGTANLSEAIRVPPTLEVTQQPMRVGNQVNVTCQVRKFYP QSLQLTWSENGNVCQRETASTLTENKDGTYNWTSWFLVNISDQRDDVVLT CQVKHDGQLAVSKRLALEVTVHQKDQSSDATPGPAS |
| 预测分子量 | 64 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SIRPG重组蛋白的3篇代表性文献及其摘要概括：
1. **文献名称**：*Structural and functional characterization of recombinant human SIRPγ and its interaction with CD47*
**作者**：Smith A, et al.
**摘要**：该研究解析了重组人源SIRPγ蛋白的晶体结构，揭示了其与CD47结合的独特表位，并通过体外实验证明SIRPγ可通过竞争性抑制SIRPα-CD47通路增强巨噬细胞对肿瘤细胞的吞噬作用。
2. **文献名称**：*SIRPγ recombinant protein modulates T cell activation in autoimmune disease models*
**作者**：Wang L, et al.
**摘要**：研究利用重组SIRPγ蛋白探究其在自身免疫疾病中的调节作用，发现其通过抑制T细胞受体信号通路降低炎症因子释放，并在小鼠类风湿性关节炎模型中缓解了疾病进展。
3. **文献名称**：*Development of a high-yield SIRPγ-Fc fusion protein for cancer immunotherapy*
**作者**：Chen X, et al.
**摘要**：该文献报道了一种新型SIRPγ-Fc重组融合蛋白的制备工艺，通过哺乳动物细胞表达系统实现高产量纯化，并验证其可通过阻断CD47-SIRPα免疫检查点增强抗肿瘤免疫应答。
4. **文献名称**：*SIRPγ recombinant variants enhance dendritic cell cross-presentation in viral infection*
**作者**：Rodriguez M, et al.
**摘要**：研究设计了一系列SIRPγ胞外域重组突变体，证明特定突变体可通过激活树突状细胞的抗原提呈功能，显著提升抗病毒T细胞反应，为疫苗佐剂开发提供新策略。
(注：以上文献为示例性内容，实际文献需通过学术数据库检索确认。)
**Background of SIRPG Recombinant Protein**
SIRPG (Signal-Regulatory Protein Gamma) is a member of the SIRP family, a group of transmembrane glycoproteins involved in immune regulation. Structurally, SIRPG contains immunoglobulin-like domains in its extracellular region, facilitating interactions with ligands on neighboring cells, and a short cytoplasmic tail lacking signaling motifs, suggesting roles in modulating cell-surface signaling. Unlike SIRPα, which binds CD47 to mediate "don't eat me" signals in macrophages, SIRPG exhibits distinct ligand specificity, potentially engaging with alternative partners to regulate immune cell activity.
Functionally, SIRPG is prominently expressed on T cells and natural killer (NK) cells, where it influences immune synapse formation and cellular activation. Studies suggest its involvement in fine-tuning adaptive immune responses, such as enhancing T-cell receptor signaling or modulating cytotoxicity. Its role in immune homeostasis makes it a potential target for therapeutic intervention.
Recombinant SIRPG protein, produced via expression systems like mammalian cells (e.g., CHO) to ensure proper post-translational modifications, serves as a critical tool for studying its biological mechanisms. Researchers utilize it to map ligand interactions, dissect signaling pathways, and develop blocking antibodies or fusion proteins. In immunotherapy, targeting SIRPG may offer strategies to either amplify anti-tumor immunity (e.g., in checkpoint-resistant cancers) or suppress autoimmune reactions by altering T-cell activation thresholds.
Current preclinical studies explore SIRPG's therapeutic potential, particularly in oncology and autoimmune diseases, though clinical applications remain emerging. Its unique positioning in immune regulation underscores its relevance in advancing precision medicine and novel immunomodulatory therapies.
×
